Systematic review: The efficacy of herbal therapy in inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 8, 2013, Pages 854-863

  Ng, S C ^a   Lam, Y T ^a   Tsoi, K K F ^a   Chan, F K L ^a   Sung, J J Y ^a   Wu, J C Y ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANDROGRAPHIS PANICULATA EXTRACT; BOSWELLIA SERRATA EXTRACT; CURCUMIN; DEXAMETHASONE; ENEMA; HERBACEOUS AGENT; HMPL 004; MESALAZINE; NEOMYCIN; OMEGA 3 FATTY ACID; PLACEBO; PREDNISOLONE; RESIN; SALAZOSULFAPYRIDINE; STEROID; UNCLASSIFIED DRUG; VITAMIN B GROUP;

ABDOMINAL PAIN; ADULT; ALOE VERA; ANDROGRAPHIS PANICULATA; ARTEMISIA ABSINTHIUM; BOSWELLIA SERRATA; COLOSTRUM; CONSTIPATION; CROHN DISEASE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EVENING PRIMROSE; FEMALE; FLATULENCE; FLOWER; HERBAL MEDICINE; HUMAN; LOW DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; PLANT ROOT; PLANT SEED; PLANTAGO OVATA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM HEMORRHAGE; REMISSION; REVIEW; SOPHORA FLAVESCENS; SYSTEMATIC REVIEW; TRIPTERYGIUM WILFORDII; TRITICUM AESTIVUM; ULCERATIVE COLITIS;

COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; PHYTOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84884908772     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12464     Document Type: Review

References (50)

1. Kane SV, Robinson A,. Review article: understanding adherence to medication in ulcerative colitis-innovative thinking and evolving concepts. Aliment Pharmacol Ther 2010; 32: 1051-8.
2. Toruner M, Loftus EV Jr, Harmsen WS, et al,. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008; 134: 929-36.
3. Lichtenstein GR, Rutgeerts P, Sandborn WJ, et al,. A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol 2012; 107: 1051-63.
4. Fernandez A, Barreiro-de AM, Vallejo N, et al,. Complementary and alternative medicine in inflammatory bowel disease patients: frequency and risk factors. Dig Liver Dis 2012; 44: 904-8.
5. Hilsden RJ, Verhoef MJ, Rasmussen H, Porcino A, deBruyn JC,. Use of complementary and alternative medicine by patients with inflammatory bowel disease. Inflamm Bowel Dis 2011; 17: 655-62.
6. Lakatos PL, Czegledi Z, David G, et al,. Association of adherence to therapy and complementary and alternative medicine use with demographic factors and disease phenotype in patients with inflammatory bowel disease. J Crohns Colitis 2010; 4: 283-90.
7. Opheim R, Hoivik ML, Solberg IC, Moum B,. Complementary and alternative medicine in patients with inflammatory bowel disease: the results of a population-based inception cohort study (IBSEN). J Crohns Colitis 2012; 6: 345-53.
8. Opheim R, Bernklev T, Fagermoen MS, Cvancarova M, Moum B,. Use of complementary and alternative medicine in patients with inflammatory bowel disease: results of a cross-sectional study in Norway. Scand J Gastroenterol 2012; 47: 1436-47.
9. Rawsthorne P, Clara I, Graff LA, et al,. The Manitoba Inflammatory Bowel Disease Cohort Study: a prospective longitudinal evaluation of the use of complementary and alternative medicine services and products. Gut 2012; 61: 521-7.
10. Weizman AV, Ahn E, Thanabalan R, et al,. Characterisation of complementary and alternative medicine use and its impact on medication adherence in inflammatory bowel disease. Aliment Pharmacol Ther 2012; 35: 342-9.
11. Wong AP, Clark AL, Garnett EA, et al,. Use of complementary medicine in pediatric patients with inflammatory bowel disease: results from a multicenter survey. J Pediatr Gastroenterol Nutr 2009; 48: 55-60.
12. Leong RW, Lawrance IC, Ching JY, et al,. Knowledge, quality of life, and use of complementary and alternative medicine and therapies in inflammatory bowel disease: a comparison of Chinese and Caucasian patients. Dig Dis Sci 2004; 49: 1672-6.
13. Langhorst J, Anthonisen IB, Steder-Neukamm U, et al,. Patterns of complementary and alternative medicine (CAM) use in patients with inflammatory bowel disease: perceived stress is a potential indicator for CAM use. Complement Ther Med 2007; 15: 30-7.
14. Langhorst J, Anthonisen IB, Steder-Neukamm U, et al,. Amount of systemic steroid medication is a strong predictor for the use of complementary and alternative medicine in patients with inflammatory bowel disease: results from a German national survey. Inflamm Bowel Dis 2005; 11: 287-95.
15. Jonkers D, Penders J, Masclee A, Pierik M,. Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients. Drugs 2012; 72: 803-23.
16. Heilpern D, Szilagyi A,. Manipulation of intestinal microbial flora for therapeutic benefit in inflammatory bowel diseases: review of clinical trials of probiotics, pre-biotics and synbiotics. Rev Recent Clin Trials 2008; 3: 167-84.
17. Butterworth AD, Thomas AG, Akobeng AK,. Probiotics for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2008;(3): CD006634.
18. MacLean CH, Mojica WA, Newberry SJ, et al,. Systematic review of the effects of n-3 fatty acids in inflammatory bowel disease. Am J Clin Nutr 2005; 82: 611-9.
19. Turner D, Shah PS, Steinhart AH, Zlotkin S, Griffiths AM,. Maintenance of remission in inflammatory bowel disease using omega-3 fatty acids (fish oil): a systematic review and meta-analyses. Inflamm Bowel Dis 2011; 17: 336-45.
20. Mu JP, Wu HG, Zhang ZQ, et al,. Meta-analysis on acupuncture and moxibustion for treatment of ulcerative colitis. Zhongguo Zhen Jiu 2007; 27: 687-90.
21. Langmead L, Feakins RM, Goldthorpe S, et al,. Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis. Aliment Pharmacol Ther 2004; 19: 739-47.
22. Ben-Arye E, Goldin E, Wengrower D, Stamper A, Kohn R, Berry E,. Wheat grass juice in the treatment of active distal ulcerative colitis: a randomized double-blind placebo-controlled trial. Scand J Gastroenterol 2002; 37: 444-9.
23. Khan Z, Macdonald C, Wicks AC, et al,. Use of the 'nutriceutical', bovine colostrum, for the treatment of distal colitis: results from an initial study. Aliment Pharmacol Ther 2002; 16: 1917-22.
24. Gupta I, Parihar A, Malhotra P, et al,. Effects of gum resin of Boswellia serrata in patients with chronic colitis. Planta Med 2001; 67: 391-5.
25. Tang T, Targan SR, Li ZS, Xu C, Byers VS, Sandborn WJ,. Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis-a double-blind comparison with sustained release mesalazine. Aliment Pharmacol Ther 2010; 33: 194-202.
26. Chen ZS, Nie ZW, Sun QL,. Clinical study in treating intractable ulcerative colitis with traditional Chinese medicine. Zhongguo Zhong Xi Yi Jie He Za Zhi 1994; 14: 400-2.
27. Wang B, Ren S, Feng W, Zhong Z, Qin C,. Kui jie qing in the treatment of chronic non-specific ulcerative colitis. J Tradit Chin Med 1997; 17: 10-3.
28. Chen Q, Zhang H,. Clinical study on 118 cases of ulcerative colitis treated by integration of traditional Chinese and Western medicine. J Tradit Chin Med 1999; 19: 163-5.
29. Hanai H, Iida T, Takeuchi K, et al,. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006; 4: 1502-6.
30. Fernandez-Banares F, Hinojosa J, Sanchez-Lombrana JL, et al,. Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU). Am J Gastroenterol 1999; 94: 427-33.
31. Greenfield SM, Green AT, Teare JP, et al,. A randomized controlled study of evening primrose oil and fish oil in ulcerative colitis. Aliment Pharmacol Ther 1993; 7: 159-66.
32. Hanai H, Kanauchi O, Mitsuyama K, et al,. Germinated barley foodstuff prolongs remission in patients with ulcerative colitis. Int J Mol Med 2004; 13: 643-7.
33. Sandborn WJ, Targan SR, Byers VS, et al,. Andrographis paniculata extract (HMPL-004) for active ulcerative colitis. Am J Gastroenterol 2013; 108: 90-8.
34. Zhang F, Li Y, Xu F, Chu Y, Zhao W,. Comparison of Xilei-san, a Chinese Herbal Medicine, and Dexamethasone in Mild/Moderate Ulcerative Proctitis: a Double-Blind Randomized Clinical Trial. J Altern Complement Med 2013 [Epub ahead of print].
35. Fukunaga K, Ohda Y, Hida N, et al,. Placebo controlled evaluation of Xilei San, a herbal preparation in patients with intractable ulcerative proctitis. J Gastroenterol Hepatol 2012; 27: 1808-15.
36. Omer B, Krebs S, Omer H, Noor TO,. Steroid-sparing effect of wormwood (Artemisia absinthium) in Crohn's disease: a double-blind placebo-controlled study. Phytomedicine 2007; 14: 87-95.
37. Krebs S, Omer TN, Omer B,. Wormwood (Artemisia absinthium) suppresses tumour necrosis factor alpha and accelerates healing in patients with Crohn's disease-A controlled clinical trial. Phytomedicine 2010; 17: 305-9.
38. Gerhardt H, Seifert F, Buvari P, Vogelsang H, Repges R,. Therapy of active Crohn disease with Boswellia serrata extract H 15. Z Gastroenterol 2001; 39: 11-7.
39. Holtmeier W, Zeuzem S, Preibeta J, et al,. Randomized, placebo-controlled, double-blind trial of Boswellia serrata in maintaining remission of Crohn's disease: good safety profile but lack of efficacy. Inflamm Bowel Dis 2010; 17: 573-82.
40. Tao QS, Ren JA, Ji ZL, Li JS, Wang XB, Jiang XH,. Maintenance effect of polyglycosides of Tripterygium wilfordii on remission in postoperative Crohn disease. Zhonghua Wei Chang Wai Ke Za Zhi 2009; 12: 491-3.
41. Liao NS, Ren JA, Fan CG, Wang GF, Zhao YZ, Li JS,. Efficacy of polyglycosides of Tripterygium wilfordii in preventing postoperative recurrence of Crohn disease. Zhonghua Wei Chang Wai Ke Za Zhi 2009; 12: 167-9.
42. Ren J, Tao Q, Wang X, Wang Z, Li J,. Efficacy of T2 in active Crohn's disease: a prospective study report. Dig Dis Sci 2007; 52: 1790-7.
43. Quattropani C, Ausfeld B, Straumann A, Heer P, Seibold F,. Complementary alternative medicine in patients with inflammatory bowel disease: use and attitudes. Scand J Gastroenterol 2003; 38: 277-82.
44. Bensoussan M, Jovenin N, Garcia B, et al,. Complementary and alternative medicine use by patients with inflammatory bowel disease: results from a postal survey. Gastroenterol Clin Biol 2006; 30: 14-23.
45. Ganguli SC, Cawdron R, Irvine EJ,. Alternative medicine use by Canadian ambulatory gastroenterology patients: secular trend or epidemic? Am J Gastroenterol 2004; 99: 319-26.
46. Hilsden RJ, Verhoef MJ, Best A, Pocobelli G,. Complementary and alternative medicine use by Canadian patients with inflammatory bowel disease: results from a national survey. Am J Gastroenterol 2003; 98: 1563-8.
47. Langmead L, Chitnis M, Rampton DS,. Use of complementary therapies by patients with IBD may indicate psychosocial distress. Inflamm Bowel Dis 2002; 8: 174-9.
48. Langmead L, Rampton DS,. Review article: complementary and alternative therapies for inflammatory bowel disease. Aliment Pharmacol Ther 2006; 23: 341-9.
49. Hilsden RJ, Scott CM, Verhoef MJ,. Complementary medicine use by patients with inflammatory bowel disease. Am J Gastroenterol 1998; 93: 697-701.
50. Ernst E, Pittler MH,. Alternative therapy bias. Nature 1997; 385: 480.